New study aims to predict dangerous side effects of cancer immunotherapy

NCT ID NCT05139706

Recruiting now Knowledge-focused Sponsor: Sir Mortimer B. Davis - Jewish General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects medical information and biological samples (blood, tissue, stool) from 1,000 cancer patients receiving immune checkpoint inhibitors. The goal is to understand why some patients develop immune-related side effects and find ways to predict and manage them. Participants include cancer patients on immunotherapy, people with autoimmune conditions, and healthy volunteers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could lead to ways to predict and manage immune-related side effects from cancer immunotherapy, making treatment safer.
What could go wrong: This is an observational study, not a treatment trial. It may not directly benefit participants, and findings may take years to translate into clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease cancer immune system disorder Inflammation inflammatory disease neoplasm type 1 diabetes mellitus 12

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES CANCER IMMUNE SYSTEM DISORDER INFLAMMATORY REACTION

Contacts and locations

Locations

Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T 1E2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.